Literature DB >> 30404751

Persistent Atrial Fibrillation Ablation: Where Do We Go From Here?

Atul Verma1, Laurent Macle2.   

Abstract

Catheter ablation is being used increasingly for the treatment of atrial fibrillation (AF). Pulmonary vein antral isolation is considered the "cornerstone" for the ablation of AF. This approach has demonstrated consistent rates of success for paroxysmal AF, but the rates of success for persistent AF are lower. There has long been a hypothesis that additional ablation beyond pulmonary vein isolation is required to achieve better outcomes in the population with persistent AF. However, large clinical trials have demonstrated recently that such approaches as empiric linear ablation and/or ablation of complex fractionated electrograms may add no benefit over pulmonary vein isolation alone in persistent AF. Furthermore, new technologies are improving the durability and outcome of pulmonary vein isolation alone. These observations have endorsed a search for new potential targets for adjuvant ablation, which currently include ablation of dynamic phenomena during AF such as rotational and focal activations, ablation of scar regions in the atria, isolation of the left atrial posterior wall, and ablation of nonpulmonary vein triggers. Whether any of these additional approaches will add to the success of ablation for persistent AF is unknown. Smaller study results are mixed. Only the performance of large-scale randomized trials will definitively answer whether additional ablation over pulmonary vein isolation alone with improve outcomes for persistent AF.
Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30404751     DOI: 10.1016/j.cjca.2018.08.008

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

1.  Catheter ablation: an ongoing revolution.

Authors:  Alexandre Raymond-Paquin; Jason Andrade; Laurent Macle
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

Review 2.  Comparing the efficacy of catheter ablation strategies for persistent atrial fibrillation: a Bayesian analysis of randomized controlled trials.

Authors:  Sijia Wu; Hongkai Li; Shaolei Yi; Jianming Yao; Xueming Chen
Journal:  J Interv Card Electrophysiol       Date:  2022-07-04       Impact factor: 1.900

3.  Differences in Healthcare Use Between Patients With Persistent and Paroxysmal Atrial Fibrillation Undergoing Catheter-Based Atrial Fibrillation Ablation: A Population-Based Cohort Study From Ontario, Canada.

Authors:  Andrew C T Ha; Harindra C Wijeysundera; Feng Qiu; Kayley Henning; Kamran Ahmad; Paul Angaran; David H Birnie; Eugene Crystal; Andrew H Ha; Jeff S Healey; Peter Leong-Sit; Bhavanesh Makanjee; Pablo B Nery; Damian P Redfearn; Allan C Skanes; Atul Verma
Journal:  J Am Heart Assoc       Date:  2020-12-31       Impact factor: 5.501

Review 4.  Recent clinical trials in atrial fibrillation.

Authors:  Thomas Flautt; Miguel Valderrábano
Journal:  Curr Opin Cardiol       Date:  2021-11-01       Impact factor: 2.108

5.  Circular RNA mmu_circ_0005019 inhibits fibrosis of cardiac fibroblasts and reverses electrical remodeling of cardiomyocytes.

Authors:  Na Wu; Chengying Li; Li Zhong; Yafei Li; Bin Xu; Ying Xiang; Xiaoyue Jia; Zhiquan Yuan; Long Wu
Journal:  BMC Cardiovasc Disord       Date:  2021-06-21       Impact factor: 2.298

6.  Atrial Remodeling in Atrial Fibrillation. Comorbidities and Markers of Disease Progression Predict Catheter Ablation Outcome.

Authors:  Judit Szilágyi; László Sághy
Journal:  Curr Cardiol Rev       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.